Please assess the completion status of the following clinical trial:

Trial Title: A Study In Adults With Moderate To Severe Dermatomyositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for Patients with Skin Predominant Activity:~* Must have CDASI Activity score of greater than or equal to 14, and have failed at least 1 standard of care systemic treatment, (eg, corticosteroids).~* Confirmation of DM by the investigator and two of the following:~  1. Gottron's papules;~ 2. Gottron's sign;~ 3. Heliotrope eruption;~ 4. Nailfold changes, (dilated capillary loops, capillary dropout, cuticular hypertrophy and/or rugged cuticles;~ 5. Photodistributed violaceous erythema, (skin that is exposed to sunlight and appears purplish/reddish, and patchy in appearance;~ 6. Positive DM serology -~* Post DM diagnosis; standard of care workup for DM must have been completed prior to entry into this research study.~* Willing to provide 8 biopsies during the course of the research study~Inclusion Criteria for Patients with Muscle Predominant Activity:~* MMT-8 ≤136/150 and PhGA, VAS ≥3 cm (0-10 cm) by visual analog scale (VAS)~* Sum of PhGA, VAS, PtGA, and extramuscular global assessment VAS scores is ≥10 cm (0-10 cm) VAS for each.~  * Participant has failed at least two or more adequate courses of an immunosuppressive agent or immunomodulatory agent, including IVIG, at a dose known to be effective for rheumatologic diseases.~Exclusion Criteria for Patients with Skin Predominant Activity:~* Investigator site staff or members of their family.~* Acute and Chronic present medical conditions~* Intake of greater than 15 mg of prednisone or equivalent per day~* Pregnant or breastfeeding females. Fertile men and women who will not comply with the use of 2 effective birth control methods as per the research protocol~* Have required management of acute or chronic infections~* Have pre existing demyelinating disorder such as multiple sclerosis, or other severe neurological deficits.~* Clinically significant lab abnormalities~* Any health condition that may be worsened by immunosuppression~Exclusion Criteria for Patients with Muscle Predominant Activity:~Similar to patients with skin predominant activity; Intake of \>20 mg oral prednisone/day, or equivalent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo ARM (Type: PLACEBO_COMPARATOR): None
- PF-06823859 ARM high (Type: EXPERIMENTAL): None
- PF-06823859 ARM low (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).